Rawlins: from NICE to new key body?
This article was originally published in Clinica
Professor Sir Michael Rawlins, who until last month chaired the UK’s National Institute for Health and Care Excellence (NICE) for 13 years (www.clinica.co.uk, 2 April 2013), is rumored to have been tapped to head one of the NHS’s incipient Academic Health Science Networks (AHSN), according to a Clinica source. A total of 15 AHSNs are planned for England – these networks will act as forums for NHS academia, industry and other stakeholders to collaborate on best practice and getting innovation into the health system (www.clinica.co.uk, 9 May 2013). Having someone with Prof Rawlins’ long background in HTA on board to head an AHSN would significantly raise the profile of these organizations and underline the key role that they are expected to play in the innovation-pushing machinery of the new NHS (www.clinica.co.uk, 18 March 2013).
You may also be interested in...
The World Trade Organization is not the place to discuss pharmaceutical pricing, and strong intellectual property rights do not threaten access to medicines, according to EU and US delegations to the WTO.
How do the EU’s new MDR cybersecurity guidelines expand on the MDR and fit into the myriad other software-related guidance documents the medtech industry has to consider?
Bio-Thera, which has just started selling China’s first adalimumab biosimilar rival to AbbVie’s top-selling arthritis treatment Humira, has raised $241m in an IPO on the Shanghai Stock Exchange.